Tags : Novel Microbiome Therapies

Biotech

Takeda Signs an Exclusive License and Research Agreement with Debiopharm

Shots: Takeda will screen & optimize compounds derived from Debiopharm’s Debio 1454M program to identify candidates for further development to treat IBD and other GI disorders Takeda will pursue the development of a novel preclinical narrow spectrum microbiome remodeling program. The candidates will be evaluated for their effectiveness against specific disease-causing microorganisms while preserving the […]Read More